Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Mulligan

Showing results (1-10 of 192) with videos related to

Pageof 20
Sort By:
Current Infectious Disease Reports|August 25, 2009
Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventionsMark J Mulligan
JAMA|August 14, 2020
An Inactivated Virus Candidate Vaccine to Prevent COVID-19Mark J Mulligan
The Journal of Infectious Diseases|June 11, 2009
The imperative of influenza vaccines for elderly individuals-an evolving storyGregory A Poland, Mark J Mulligan
Current Opinion in Virology|June 11, 2016
Editorial overview: Preventive and therapeutic vaccinesHarriet L Robinson, Mark J Mulligan
Oncotarget|December 8, 2017
Microneedle patch for immunization of immunocompromised hostsNadine G Rouphael, Mark J Mulligan
JAMA|April 15, 2020
A New Vaccine for Chikungunya VirusKenneth A Stapleford, Mark J Mulligan
The Lancet. Infectious Diseases|September 1, 2015
Era of global Ebola: risk of exposure in health-care workersMark J Mulligan, Paul N Siebert
Journal of Virology|January 29, 2003
Foamy virus envelope glycoprotein is sufficient for particle budding and releaseKit L Shaw, Dirk Lindemann, Mark J Mulligan, et al.
Challenge (Atlanta, Ga.)|August 6, 2010
Promoting HIV Vaccine Research in African American Communities: Does the Theory of Reasoned Action Explain Potential Outcomes of Involvement?Paula M Frew, Matthew Archibald, Nina Martinez, et al.
The Lancet. Infectious Diseases|November 24, 2012
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1Jennifer A Whitaker, Nadine G Rouphael, Srilatha Edupuganti, et al.
Pageof 20

Showing results (1-10 of 192) with videos related to

Sort By:
Pageof 20
Current Infectious Disease Reports|August 25, 2009
Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventionsMark J Mulligan
JAMA|August 14, 2020
An Inactivated Virus Candidate Vaccine to Prevent COVID-19Mark J Mulligan
The Journal of Infectious Diseases|June 11, 2009
The imperative of influenza vaccines for elderly individuals-an evolving storyGregory A Poland, Mark J Mulligan
Current Opinion in Virology|June 11, 2016
Editorial overview: Preventive and therapeutic vaccinesHarriet L Robinson, Mark J Mulligan
Oncotarget|December 8, 2017
Microneedle patch for immunization of immunocompromised hostsNadine G Rouphael, Mark J Mulligan
JAMA|April 15, 2020
A New Vaccine for Chikungunya VirusKenneth A Stapleford, Mark J Mulligan
The Lancet. Infectious Diseases|September 1, 2015
Era of global Ebola: risk of exposure in health-care workersMark J Mulligan, Paul N Siebert
Journal of Virology|January 29, 2003
Foamy virus envelope glycoprotein is sufficient for particle budding and releaseKit L Shaw, Dirk Lindemann, Mark J Mulligan, et al.
Challenge (Atlanta, Ga.)|August 6, 2010
Promoting HIV Vaccine Research in African American Communities: Does the Theory of Reasoned Action Explain Potential Outcomes of Involvement?Paula M Frew, Matthew Archibald, Nina Martinez, et al.
The Lancet. Infectious Diseases|November 24, 2012
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1Jennifer A Whitaker, Nadine G Rouphael, Srilatha Edupuganti, et al.
Pageof 20